Categories: BrainDiagnosticsNews

DiamiR Biosciences Secures EU Patent Covering the Use of microRNA Biomarkers from Bodily Fluids for Differential Diagnosis of Amyotrophic Lateral Sclerosis

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

NEW HAVEN, CT, and MONMOUTH JUNCTION, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) — DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced that the Company’s European Patent Application No. 17 771018.3 titled: “Methods of using miRNAs from bodily fluids for detection and differentiation of neurodegenerative diseases” was granted by the European Patent Office under number 3 433 381. The patent, which is set to expire in March 2037, claims the use of methods developed by DiamiR for early diagnosis of amyotrophic lateral sclerosis (ALS).

The corresponding US patent application No. 16/086,881 was granted by the United States Patent & Trademark Office (USPTO) on October 19, 2021 as US 4,149,313 with claims to detecting and monitoring neurodegenerative disorders in association with treatment.

DiamiR now has 52 issued patents in the US and worldwide comprising seven families of patents and covering early detection, differential diagnosis, and monitoring of disease and aging with microRNA signatures detectable in bodily fluids, including blood plasma.

“Allowance of this new patent by the European Patent Office further strengthens DiamiR’s global IP portfolio focused on early detection, prediction of progression and monitoring of brain health and other conditions,” said Dr. Samuil Umansky, Chief Scientific Officer of DiamiR. “In DiamiR’s ongoing biomarker programs, our main objective is to provide researchers and clinicians with minimally invasive, accurate molecular solutions for better characterization of patients and monitoring disease severity and progression as well as response to treatment during drug development.”

About DiamiR

DiamiR is a privately held molecular diagnostics company focused on developing minimally invasive tests for detection and monitoring of pathology based on quantitative analysis of organ-enriched microRNA signatures in plasma for screening, patient stratification, as well as disease progression and treatment monitoring. DiamiR collaborates with leading academic centers, disease foundations, and biopharma companies. For more information, please visit the company’s website at www.diamirbio.com.

This news release contains forward-looking statements regarding future events. These statements are predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Contact: 
Alidad Mireskandari, PhD
203-570-8275
amireskandari@diamirbio.com

Staff

Recent Posts

lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics

SAN DIEGO, June 10, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), aligned with its commitments…

3 hours ago

Applied Medical Technology, Inc. Unveils Redesigned Mobile App Aligned with Recent Website Refresh

BRECKSVILLE, Ohio., June 10, 2025 /PRNewswire/ -- Applied Medical Technology, Inc. (AMT), a leader in innovative…

3 hours ago

NCPDP Foundation Awards $200,000 Grant to CARIN Alliance for Consumer-Facing Real-Time Pharmacy Benefit Check Project

SCOTTSDALE, Ariz., June 10, 2025 /PRNewswire/ -- The NCPDP Foundation is pleased to announce the approval…

3 hours ago

CSD Charts a New Course for Career Growth with Launch of Career Rewards

Milestone recognition, mentorship, and advancement opportunities come together as part of the Career Compass initiative…

3 hours ago

The YMCA of Metropolitan Chicago Names Adam M. Alonso as Next President and CEO

Veteran nonprofit executive and youth development champion Adam M. Alonso named President and CEO of…

3 hours ago

Santa Clara Family Health Plan renews partnership with Ushur, Inc., to better serve members through targeted digital text messaging

SAN JOSÉ, Calif., June 10, 2025 /PRNewswire/ -- Santa Clara Family Health Plan (SCFHP) is proud…

3 hours ago